Published in Clin Vaccine Immunol on October 03, 2012
Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev (2013) 2.43
Conservation and immunogenicity of novel antigens in diverse isolates of enterotoxigenic Escherichia coli. PLoS Negl Trop Dis (2015) 1.44
Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). PLoS One (2015) 1.43
Identification of enterotoxigenic Escherichia coli (ETEC) clades with long-term global distribution. Nat Genet (2014) 1.24
Enterotoxigenic Escherichia coli secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells. Infect Immun (2013) 1.01
EatA, an immunogenic protective antigen of enterotoxigenic Escherichia coli, degrades intestinal mucin. Infect Immun (2013) 0.99
Novel antigens for enterotoxigenic Escherichia coli vaccines. Expert Rev Vaccines (2014) 0.90
A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles. Front Microbiol (2015) 0.89
Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea. Clin Vaccine Immunol (2015) 0.87
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. Hum Vaccin Immunother (2015) 0.84
Contribution of the highly conserved EaeH surface protein to enterotoxigenic Escherichia coli pathogenesis. Infect Immun (2014) 0.82
Protective Enterotoxigenic Escherichia coli Antigens in a Murine Intranasal Challenge Model. PLoS Negl Trop Dis (2015) 0.81
Enterotoxigenic Escherichia coli: Orchestrated host engagement. Gut Microbes (2013) 0.81
Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults. PLoS Negl Trop Dis (2014) 0.81
Maternal Vaccination with a Fimbrial Tip Adhesin and Passive Protection of Neonatal Mice against Lethal Human Enterotoxigenic Escherichia coli Challenge. Infect Immun (2015) 0.80
Combination vaccines against diarrheal diseases. Hum Vaccin Immunother (2015) 0.80
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli. PLoS One (2016) 0.79
Antibody-mediated disruption of the mechanics of CS20 fimbriae of enterotoxigenic Escherichia coli. Sci Rep (2015) 0.79
Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia coli. Toxins (Basel) (2014) 0.79
Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407. Clin Vaccine Immunol (2015) 0.78
Overcoming Enterotoxigenic Escherichia coli Pathogen Diversity: Translational Molecular Approaches to Inform Vaccine Design. Methods Mol Biol (2016) 0.78
Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin. Clin Vaccine Immunol (2016) 0.76
Highlights of the 8th International Conference on Vaccines for Enteric Diseases: the Scottish Encounter To Defeat Diarrheal Diseases. Clin Vaccine Immunol (2016) 0.76
Tailoring the Immune Response via Customization of Pathogen Gene Expression. J Pathog (2014) 0.75
Colonization Factors in Enterotoxigenic Escherichia coli Strains in Travelers to Mexico, Guatemala, and India Compared with Children in Houston, Texas. Am J Trop Med Hyg (2016) 0.75
Towards Rational Design of a Toxoid Vaccine against the Heat-Stable Toxin of Escherichia coli. Infect Immun (2016) 0.75
Murine immunization with CS21 pili or LngA major subunit of enterotoxigenic Escherichia coli (ETEC) elicits systemic and mucosal immune responses and inhibits ETEC gut colonization. Vet Microbiol (2016) 0.75
Antibodies damage fimbrial resilience, causing them to be stiff and tangled. J Bacteriol (2016) 0.75
Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet (2010) 26.48
Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect Immun (1975) 14.65
Estimating child mortality due to diarrhoea in developing countries. Bull World Health Organ (2008) 5.59
Three characteristics associated with enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 4.42
Enteric infections, diarrhea, and their impact on function and development. J Clin Invest (2008) 3.23
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet (2008) 2.79
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries. Wkly Epidemiol Rec (2006) 1.72
Childhood stunting: measuring and stemming the staggering costs of inadequate water and sanitation. Lancet (2004) 1.56
Economic aspects of travelers' diarrhea. J Travel Med (2008) 1.55
Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children. Gastroenterology (2010) 1.41
Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med (2005) 1.40
Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis (1998) 1.34
Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man. Scand J Infect Dis Suppl (1982) 1.26
Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine (2007) 1.18
Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology (1983) 1.16
Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiol Immunol (1988) 1.12
Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli. Infect Immun (2006) 1.11
A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). Vaccine (2011) 1.10
Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol (2011) 1.07
A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin Vaccine Immunol (2011) 0.97
Immunoprotective oral whole cell vaccine for enterotoxigenic Escherichia coli diarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2. FEMS Microbiol Immunol (1988) 0.97
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun (2006) 0.97
Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic escherichia coli-cholera toxin B subunit vaccine in Israeli young adults. Infect Immun (2000) 0.90
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. J Clin Microbiol (2002) 4.54
Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet (2005) 4.16
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. Proc Natl Acad Sci U S A (2005) 3.62
Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. J Clin Microbiol (2006) 3.60
Cholera in Mozambique, variant of Vibrio cholerae. Emerg Infect Dis (2004) 3.39
Global dissemination of Vibrio parahaemolyticus serotype O3:K6 and its serovariants. Clin Microbiol Rev (2007) 3.36
A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh. J Infect Dis (2002) 3.27
Critical factors influencing the occurrence of Vibrio cholerae in the environment of Bangladesh. Appl Environ Microbiol (2005) 3.17
Self-limiting nature of seasonal cholera epidemics: Role of host-mediated amplification of phage. Proc Natl Acad Sci U S A (2005) 2.80
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet (2008) 2.79
Reduction of cholera in Bangladeshi villages by simple filtration. Proc Natl Acad Sci U S A (2003) 2.68
Genetic diversity and virulence potential of environmental Vibrio cholerae population in a cholera-endemic area. Proc Natl Acad Sci U S A (2004) 2.59
Transmissibility of cholera: in vivo-formed biofilms and their relationship to infectivity and persistence in the environment. Proc Natl Acad Sci U S A (2006) 2.54
Enterotoxigenic Escherichia coli and Vibrio cholerae diarrhea, Bangladesh, 2004. Emerg Infect Dis (2005) 2.42
Association between climate variability and hospital visits for non-cholera diarrhoea in Bangladesh: effects and vulnerable groups. Int J Epidemiol (2007) 2.10
Invasive pneumococcal disease burden and implications for vaccine policy in urban Bangladesh. Am J Trop Med Hyg (2007) 2.06
Diarrheal epidemics in Dhaka, Bangladesh, during three consecutive floods: 1988, 1998, and 2004. Am J Trop Med Hyg (2006) 2.02
Multidrug-resistant Shigella dysenteriae type 1 in south Asia. Lancet Infect Dis (2003) 1.95
Viable but nonculturable Vibrio cholerae O1 in biofilms in the aquatic environment and their role in cholera transmission. Proc Natl Acad Sci U S A (2007) 1.89
Emergence and evolution of Vibrio cholerae O139. Proc Natl Acad Sci U S A (2003) 1.83
Toxigenic Vibrio cholerae in the aquatic environment of Mathbaria, Bangladesh. Appl Environ Microbiol (2006) 1.81
Nutrition: basis for healthy children and mothers in Bangladesh. J Health Popul Nutr (2008) 1.80
Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun (2005) 1.79
Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol (2003) 1.77
Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A (2006) 1.75
Phenotypic and genotypic characterization of serologically atypical strains of Shigella flexneri type 4 isolated in Dhaka, Bangladesh. J Clin Microbiol (2002) 1.74
Prevalence of G2P[4] and G12P[6] rotavirus, Bangladesh. Emerg Infect Dis (2007) 1.73
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Burden of stroke in black populations in sub-Saharan Africa. Lancet Neurol (2007) 1.73
Decrease in shigellosis-related deaths without Shigella spp.-specific interventions, Asia. Emerg Infect Dis (2010) 1.72
Prevalence of the pandemic genotype of Vibrio parahaemolyticus in Dhaka, Bangladesh, and significance of its distribution across different serotypes. J Clin Microbiol (2002) 1.70
Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea. J Clin Microbiol (2005) 1.67
Seasonal cholera caused by Vibrio cholerae serogroups O1 and O139 in the coastal aquatic environment of Bangladesh. Appl Environ Microbiol (2006) 1.65
Antibiotics for both moderate and severe cholera. N Engl J Med (2010) 1.59
The effect of rainfall on the incidence of cholera in Bangladesh. Epidemiology (2008) 1.58
Genetic characteristics of Matlab variants of Vibrio cholerae O1 that are hybrids between classical and El Tor biotypes. J Med Microbiol (2006) 1.55
Real-time fluorescence lifetime imaging system with a 32 x 32 0.13microm CMOS low dark-count single-photon avalanche diode array. Opt Express (2010) 1.53
Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration solution. JAMA (2006) 1.53
Behavioural comorbidity in Tanzanian children with epilepsy: a community-based case-control study. Dev Med Child Neurol (2011) 1.48
Characterization of a novel P[25],G11 human group a rotavirus. J Clin Microbiol (2005) 1.46
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg (2006) 1.46
Pandemic serovars (O3:K6 and O4:K68) of Vibrio parahaemolyticus associated with diarrhea in Mozambique: spread of the pandemic into the African continent. J Clin Microbiol (2005) 1.46
Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord (2005) 1.46
Multilocus sequence typing (MLST) analysis of Vibrio cholerae O1 El Tor isolates from Mozambique that harbour the classical CTX prophage. J Med Microbiol (2006) 1.44
Antidiarrheal effects of L-histidine-supplemented rice-based oral rehydration solution in the treatment of male adults with severe cholera in Bangladesh: a double-blind, randomized trial. J Infect Dis (2005) 1.43
Use of dipsticks for rapid diagnosis of cholera caused by Vibrio cholerae O1 and O139 from rectal swabs. J Clin Microbiol (2003) 1.42
Post-stroke carotid ultrasound findings from an incident Tanzanian population. Neuroepidemiology (2011) 1.41
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis (2003) 1.40
Phenotypic and genotypic characterization of provisional serotype Shigella flexneri 1c and clonal relationships with 1a and 1b strains isolated in Bangladesh. J Clin Microbiol (2003) 1.40
RS1 element of Vibrio cholerae can propagate horizontally as a filamentous phage exploiting the morphogenesis genes of CTXphi. Infect Immun (2002) 1.38
Diverse CTX phages among toxigenic Vibrio cholerae O1 and O139 strains isolated between 1994 and 2002 in an area where cholera is endemic in Bangladesh. J Clin Microbiol (2004) 1.37
Surveillance for invasive Streptococcus pneumoniae disease among hospitalized children in Bangladesh: antimicrobial susceptibility and serotype distribution. Clin Infect Dis (2009) 1.37
Scaling up zinc treatment of childhood diarrhoea in Bangladesh: theoretical and practical considerations guiding the SUZY Project. Health Policy Plan (2011) 1.37
Reemergence of epidemic Vibrio cholerae O139, Bangladesh. Emerg Infect Dis (2003) 1.36
Meeting cholera's challenge to Haiti and the world: a joint statement on cholera prevention and care. PLoS Negl Trop Dis (2011) 1.33
Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine (2006) 1.31
Diversity of anopheline species and their Plasmodium infection status in rural Bandarban, Bangladesh. Parasit Vectors (2012) 1.29
Enterotoxigenic Escherichia coli with STh and STp genotypes is associated with diarrhea both in children in areas of endemicity and in travelers. J Clin Microbiol (2006) 1.28
Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Health Popul Nutr (2007) 1.24
Enhancement of fruit shelf life by suppressing N-glycan processing enzymes. Proc Natl Acad Sci U S A (2010) 1.24
Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine (2012) 1.22
Genetic relatedness of ciprofloxacin-resistant Shigella dysenteriae type 1 strains isolated in south Asia. J Antimicrob Chemother (2004) 1.22
Adaptive and inflammatory immune responses in patients infected with strains of Vibrio parahaemolyticus. J Infect Dis (2003) 1.21
Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines (2012) 1.20
Isolation of Shigella dysenteriae type 1 and S. flexneri strains from surface waters in Bangladesh: comparative molecular analysis of environmental Shigella isolates versus clinical strains. Appl Environ Microbiol (2002) 1.20
When should cholera vaccine be used in cholera-endemic areas? J Health Popul Nutr (2003) 1.19
Factors determining vulnerability to diarrhoea during and after severe floods in Bangladesh. J Water Health (2008) 1.19
Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunity. Int J Epidemiol (2006) 1.19
Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis (2005) 1.19
Comparative proteomics analysis of differentially expressed proteins in chickpea extracellular matrix during dehydration stress. Mol Cell Proteomics (2007) 1.19
Characterization of the Francisella tularensis subsp. novicida type IV pilus. Microbiology (2008) 1.18
Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine (2007) 1.18
Vulnerability to HIV infection among sex worker and non-sex worker female injecting drug users in Dhaka, Bangladesh: evidence from the baseline survey of a cohort study. Harm Reduct J (2006) 1.17
Time-domain fluorescence lifetime imaging techniques suitable for solid-state imaging sensor arrays. Sensors (Basel) (2012) 1.17
CTXphi-independent production of the RS1 satellite phage by Vibrio cholerae. Proc Natl Acad Sci U S A (2003) 1.15
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine (2005) 1.14
Video-rate fluorescence lifetime imaging camera with CMOS single-photon avalanche diode arrays and high-speed imaging algorithm. J Biomed Opt (2011) 1.13
Genomic relatedness of the new Matlab variants of Vibrio cholerae O1 to the classical and El Tor biotypes as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2005) 1.13
Biomechanical evaluation of periprosthetic femoral fracture fixation. J Bone Joint Surg Am (2008) 1.11
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology (2006) 1.11
Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med (2013) 1.11
Identification of a family of BspA like surface proteins of Entamoeba histolytica with novel leucine rich repeats. Mol Biochem Parasitol (2005) 1.11
Proteomics approach to identify dehydration responsive nuclear proteins from chickpea (Cicer arietinum L.). Mol Cell Proteomics (2007) 1.10
An improved technique for isolation of environmental Vibrio cholerae with epidemic potential: monitoring the emergence of a multiple-antibiotic-resistant epidemic strain in Bangladesh. J Infect Dis (2006) 1.08
O3:K6 serotype of Vibrio parahaemolyticus identical to the global pandemic clone associated with diarrhea in Peru. Int J Infect Dis (2007) 1.08
Pathogenic potential of environmental Vibrio cholerae strains carrying genetic variants of the toxin-coregulated pilus pathogenicity island. Infect Immun (2003) 1.07
Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol (2011) 1.07
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis (2006) 1.06
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect Immun (2010) 1.05
The prevalence of Parkinson's disease in rural Tanzania. Mov Disord (2008) 1.05
Dementia prevalence estimates in sub-Saharan Africa: comparison of two diagnostic criteria. Glob Health Action (2013) 1.04
The nuclear proteome of chickpea (Cicer arietinum L.) reveals predicted and unexpected proteins. J Proteome Res (2006) 1.04